Oncology & Cancer

Novel bioassay predicts cancer patients' response to immunotherapy

A team of researchers from Ben-Gurion University of the Negev (BGU) has developed a groundbreaking bio-sensing technology that predicts the response of cancer patients to anti-PD1, an immune checkpoint inhibitor (ICI) therapy, ...

page 11 from 40